MedaSystems, a Menlo Park, CA-based provider of software for access to pre-approval medicine, received additional funding from Debiopharm Innovation Fund.
The amount of the deal was not disclosed.
Led by Fiona Smythe, MedaSystems is a developer of software that streamlines the handling of requests for experimental therapies from healthcare providers, supporting both Expanded Access and Post-Trial Access. Its GxP compliant application acts as a centralized environment, connecting physicians and pharmaceutical companies to facilitate global patient access to investigational therapies. The SaaS platform facilitates the rapid processing of treatment inquiries and introduces new data capture capabilities, streamlining treatment for patients with unmet medical needs and aiding in collecting real-world data (RWD) for regulatory submissions. It ensures collaboration among key partners in situations requiring pre-approval access. Physicians can manage patient requests and oversee the entire process in-app, working with their teams and pharmacists. Pharmaceutical companies can integrate external partners like contract research organizations (CROs), guaranteeing effective communication, integrated services, and the quick shipment of treatment.
FinSMEs
09/01/2024